Schwab International Equity ETF™

Most Recent

  • uploads///
    Macroeconomic Analysis

    Analyzing the Possible Impacts of the Iran Deal Exit

    President Trump’s decision to withdraw from the Joint Comprehensive Plan of Action (or JCPOA) could lead to regional conflicts in the Middle East.

    By Ricky Cove
  • uploads///Chart  Alcon
    Earnings Report

    Novartis in 2Q17: Performance of Alcon

    For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16.

    By Mike Benson
  • uploads///Chart  Sandoz
    Earnings Report

    Novartis’s 2Q17 Estimates: How Sandoz Might Perform

    Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.

    By Mike Benson
  • uploads///Chart  NVS
    Miscellaneous

    Novartis Stock in 2Q17: How Has It Performed?

    A look at Novartis Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. The company has segregated its business into three segments: Innovative Medicines, Sandoz (generic), and Alcon (eye care). Stock price performance Novartis’s stock price has […]

    By Mike Benson
  • uploads///Chart  Inno
    Company & Industry Overviews

    Inside Novartis’s Innovative Medicines Segment in 1Q17

    Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS’s total revenues in 1Q17.

    By Mike Benson
  • uploads///Chart  Pharma
    Company & Industry Overviews

    GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17

    The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.

    By Mike Benson
  • uploads///Chart  GP
    Company & Industry Overviews

    How AstraZeneca’s Growth Platforms Performed in 1Q17

    A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.

    By Mike Benson
  • uploads///Chart  Genzyme
    Company & Industry Overviews

    Performance of Sanofi Genzyme in 1Q17

    Sanofi (SNY) reported growth of over 15% at constant exchange rates in its 1Q17 revenues from Genzyme.

    By Mike Benson
  • uploads///Chart  Developments
    Earnings Report

    Novartis’s 1Q17 Earnings: Recent Developments

    On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Novartis’s Valuation Compare to Peers?

    On January 13, 2017, Novartis was trading at a forward PE multiple of ~15.1x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of GSK’s Global Pharmaceuticals Franchises Mixed

    The global pharmaceuticals franchise is GlaxoSmithKline’s (GSK) largest revenue contributor.

    By Mike Benson
  • uploads///Returns of Japan Focused Funds in YTD
    Company & Industry Overviews

    Why an Unmoved Bank of Japan in April Shook Up Japanese Equities

    Haruhiko Kuroda, governor of the Bank of Japan, loves to give surprises. In his latest attempt, he left the monetary stance of the Bank of Japan unchanged on April 28, 2016.

    By David Ashworth
  • uploads///tm pm
    Company & Industry Overviews

    Understanding the Fall in Toyota Motor’s Sales in 2015

    Toyota Motor’s stock has technically broken support and was trading below all moving day averages on January 21.

    By Gabriel Kane
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.